This track delivers a comprehensive, real-world view of how leading organizations are operationalizing Pharma 4.0™ principles by integrating data, digital tools, and artificial intelligence (AI) into regulated environments while maintaining high standards of quality and compliance. Through expert-led sessions, it highlights actionable strategies for building connected, intelligent, and compliant pharmaceutical ecosystems.
From Data to Decisions: A New Industry Imperative
Pharma has long relied on structured processes and validated systems to ensure quality and compliance. Today’s landscape, however, demands more. With the rapid growth of data across manufacturing, quality, and supply chains, organizations are shifting toward continuous, data-driven decision-making.
The Digital, Data, and Decision Integrity track directly addresses this transition. Sessions demonstrate how to:
- Establish data integrity by design across digital ecosystems
- Implement risk-based validation approaches aligned with the ISPE GAMP® 5 Guide (Second Edition) and computer software assurance
- Govern the AI lifecycle, ensuring transparency, traceability, and compliance
- Enable real-time visibility and control through advanced analytics and connected systems
This evolving paradigm positions decision integrity alongside data integrity as a critical capability, ensuring actions are based on accurate, contextualized, and reliable insights.
AI in Action: Transforming Validation and Quality
A major highlight of the track is the role of AI in reshaping traditional processes such as computerized system validation (CSV). In the session “AI-Enabled Computerized System Validation,” Frank Henrichmann of Q-FINITY Quality Management explores how AI technologies are already improving efficiency, compliance, and quality.
Capabilities include:
- Requirement gathering, assessment, and mapping
- Automated test-case generation
- Test execution and evident capture
- Auto-generated traceability matrices
- Risk-based validation planning aligned with ISPE GAMP® 5 Guide (Second Edition) critical thinking principles
These advancements are redefining validation roles. Professionals are transitioning from documentation-focused tasks to “quality architects” responsible for designing, overseeing, and assuring intelligent validation systems.
Continuous Verification: Replacing Outdated Models
The shift from periodic review to continuous verification is another important theme. Traditional compliance approaches based on scheduled checks are increasingly insufficient in fast-moving, digital environments.
Sessions such as “Goodbye Periodic Review, Hello Continuous Verification” show how modern digital platforms enable:
- Real-time monitoring of system performance
- Immediate detection and response to deviations
- Continuous assurance of validated states
This evolution improves both inspection readiness and operational agility, ensuring that validated states are actively maintained rather than retrospectively confirmed.
Scaling AI for Product and Process Excellence
Scaling AI across global operations remains a key challenge and opportunity. In “From Reactive to Proactive: Scaling AI for Product Health,” Yiming Ping from Genentech presents a mature implementation combining statistical process control, AI/machine learning, and expert insight.
This approach enables:
- Predictive monitoring of processes
- Configurable alerts for emerging risks
- Data-driven optimization of process outputs
- Proactive, portfolio-level risk management
Such frameworks demonstrate how organizations can move beyond reactive analysis toward predictive and prescriptive decision-making within Pharma 4.0 environments.
Automating the Routine, Elevating the Strategic
AI is also proving transformative in routine, resource-intensive processes. In the session “AI Automation in Cleaning Validation Reports Writing,” two experts from Apotex highlight how automation can significantly reduce manual effort while improving consistency.
By integrating quality management system data and laboratory information management system data and applying robust statistical methodologies, organizations can:
- Automate report generation
- Ensure reproducibility and support compliance
- Accelerate validation timelines
This demonstrates a clear benefit of digital transformation by reducing non-value added work while strengthening data integrity and quality outcomes.
Building Trust in AI: Governance and Quality Assurance (QA) Evolution
With increased reliance on AI comes the need for robust governance. Sessions like “Progressive QA in AI-Enabled GxP Environments” and “Governing Human-in-the-Loop for Responsible AI” focus on ensuring AI systems remain transparent, controlled, and compliant.
Key considerations include:
- Embedding human oversight into AI processes
- Ensuring traceability and auditability of AI outputs
- Applying risk-based frameworks for model credibility and lifecycle control
- Designing systems that align with regulatory expectations
QA is evolving in this context, shifting from a traditional oversight role to a strategic architect of digital systems and processes.
The Future is Connected: Data Ecosystems and Interoperability
Beyond individual technologies, the track highlights the importance of connected data ecosystems. Initiatives like the Pharma Open Data Space illustrate how open standards and interoperability can unlock industry-wide innovation.
Benefits include:
- Breaking down data silos
- Enabling secure collaboration across organizations
- Reducing integration complexity
- Accelerating time to market
These advancements support the creation of a golden thread of data, ensuring end-to-end traceability and integrity across the product lifecycle.
Why This Track Matters
The Digital, Data, and Decision Integrity track provides a practical and forward-looking perspective on the future of pharmaceutical operations. It brings together:
- Proven frameworks aligned with Pharma 4.0
- Real-world case studies from industry leaders
- Practical strategies for AI implementation and governance
- Clear approaches to meeting evolving regulatory expectations
By focusing on the intersection of data, digital technology, and decision-making, the track highlights how organizations can improve product quality, patient safety, and operational performance in increasingly complex environments.
Join the Conversation in Washington, DC
The 2026 ISPE Annual Meeting & Expo offers a global platform for exploring the technologies, frameworks, and strategies shaping the future of the pharmaceutical industry.
The Digital, Data, and Decision Integrity track highlights how data-driven insights, digital innovation, and reliable decision-making are transforming regulated life sciences and enabling the next generation of Pharma 4.0 excellence.
Learn more and register today.
